Envista Holdings (NVST) Could Be 6% Undervalued On Q2 Earnings Focus

What triggered the latest move in Envista Holdings stock

Envista Holdings (NVST) shares moved 5.2% higher after investors focused on the company’s upcoming Q2 2026 results, due on August 5, and on expectations for revenue and earnings performance.

See our latest analysis for Envista Holdings.

That 5.2% single day move comes on top of a stronger recent trend for Envista Holdings, with a 7 day share price return of 6.15% and a year to date share price return of 28.08%. The 1 year total shareholder return of 47.06% contrasts with weaker 3 and 5 year total shareholder returns, suggesting momentum has picked up more recently as expectations around growth potential and risk have shifted.

If Envista’s latest move has you thinking about what else is gaining attention, it could be a good moment to scan other opportunities using the 41 healthcare AI stocks.

Envista Holdings now trades at a higher level after a strong short term run, yet longer term returns still lag. For new buyers, it is worth considering whether the current valuation still offers an appealing balance of risk and reward, or whether this has already been fully reflected.

Most Popular Narrative: 6.4% Undervalued

Envista Holdings closed at $27.78 compared with a narrative fair value estimate of $29.69, which points to a modest undervaluation based on that framework and a discount rate of 8.2%.

Increasing R&D investment (up 14% year-over-year) and successful launches of digital and AI-driven products (e.g., DTX Studio Clinic with AI, DEXIS CDCTs, Spark product line) enhance Envista's ability to capitalize on growing demand for digital dentistry, supporting both future revenue growth and gross margin expansion.

Read the complete narrative. Read the complete narrative.

Want to understand why this fair value sits above today’s share price? The narrative leans on measured revenue expansion, rising margins, and a future earnings multiple that assumes stronger profitability.

Result: Fair Value of $29.69 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Envista Holdings story also hinges on how it manages China volume-based procurement pressure and tariff-related cost headwinds that could unsettle the current thesis.

Find out about the key risks to this Envista Holdings narrative.

Another view on Envista Holdings valuation

The narrative fair value suggests Envista Holdings is modestly undervalued at $29.69 versus the $27.78 share price. The P/E picture looks very different. Envista trades on 66.8x earnings compared with a fair ratio of 31.1x, the US Medical Equipment industry at 29.3x, and peers at 46.4x. That gap points to higher valuation risk if sentiment or forecasts change.

For a fuller breakdown of how these earnings multiples compare with industry and peer benchmarks, and where the fair ratio suggests the market could move toward next, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With Envista Holdings now back in focus, sentiment is clearly picking up around its potential rewards. Take a closer look at the underlying data, decide quickly where you stand, and then review the 3 key rewards

Looking for more ideas beyond Envista Holdings?

If Envista Holdings has your attention, now is the moment to widen your watchlist with other stocks that could suit your style before the next move passes by.

• Target potential mispricing by scanning 56 high quality undervalued stocks that combine solid fundamentals with room for sentiment to improve.
• Build a steadier income stream by focusing on 8 dividend fortresses that offer higher yields supported by underlying business strength.
• Prioritise resilience by reviewing 89 resilient stocks with low risk scores that score well on financial health and business risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com